NCT04280913

Brief Summary

As of February 17th, 2020, China has 70635 confirmed cases of coronavirus disease 2019 (COVID-19), including 1772 deaths. Human-to-human spread of virus via respiratory droplets is currently considered to be the main route of transmission. The number of patients increased rapidly but the impact factors of clinical outcomes among hospitalized patients are still unclear.

Trial Health

30
At Risk

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Trial has exceeded expected completion date
Timeline
Completed

Started Feb 2020

Shorter than P25 for all trials

Geographic Reach
1 country

1 active site

Status
withdrawn

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

February 20, 2020

Completed
1 day until next milestone

First Posted

Study publicly available on registry

February 21, 2020

Completed
1 day until next milestone

Study Start

First participant enrolled

February 22, 2020

Completed
1 month until next milestone

Primary Completion

Last participant's last visit for primary outcome

March 31, 2020

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

March 31, 2020

Completed
Last Updated

March 19, 2020

Status Verified

March 1, 2020

Enrollment Period

1 month

First QC Date

February 20, 2020

Last Update Submit

March 17, 2020

Conditions

Coronavirus Disease 2019

Outcome Measures

Primary Outcomes (1)

  • Time to negative conversion of severe acute respiratory syndrome coronavirus 2

    The primary outcome is the time to negative conversion of coronavirus

    1 month

Secondary Outcomes (3)

  • Length of stay in hospital

    1 month

  • Survival

    1 month

  • Intubation

    1 month

Study Arms (1)

COVID-19 patients

Hospitalized patients with COVID-19

Other: retrospective analysis

Interventions

retrospective analysisOTHER

The investigators retrospectively analyzed the hospitalized patients with COVID-19.

COVID-19 patients

Eligibility Criteria

Sexall
Healthy VolunteersNo
Age GroupsChild (0-17), Adult (18-64), Older Adult (65+)
Sampling MethodNon-Probability Sample
Study Population

This is a retrospective study of hospitalized patients with COVID19.

You may qualify if:

  • Hospitalized patients with COVID19

You may not qualify if:

  • Suspected patients with COVID19, not confirmed by the laboratory
  • Patients who are refused to receive medical treatments

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

HuiZhou Municipal Central Hospital

Huizhou, Guangdong, 516001, China

Location

MeSH Terms

Conditions

COVID-19

Condition Hierarchy (Ancestors)

Pneumonia, ViralPneumoniaRespiratory Tract InfectionsInfectionsVirus DiseasesCoronavirus InfectionsCoronaviridae InfectionsNidovirales InfectionsRNA Virus InfectionsLung DiseasesRespiratory Tract Diseases

Study Officials

  • Luqian Zhou, MD

    The First Affiliated Hospital of Guangzhou Medical University

    PRINCIPAL INVESTIGATOR
0

Study Design

Study Type
observational
Observational Model
COHORT
Time Perspective
RETROSPECTIVE
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Principal Investigator

Study Record Dates

First Submitted

February 20, 2020

First Posted

February 21, 2020

Study Start

February 22, 2020

Primary Completion

March 31, 2020

Study Completion

March 31, 2020

Last Updated

March 19, 2020

Record last verified: 2020-03

Locations

CN(1)